Hirotomo Nakashima

Years Active: 2022-2022
Publications (10 Years): 1

This page only lists publications with an associated author ORCID identifier.

Publications

Chihiro Yamamoto, Daisuke Minakata, Shunsuke Koyama, Kaoru Sekiguchi, Yuta Fukui, Rui Murahashi, Hirotomo Nakashima, Sae Matsuoka, Takashi Ikeda, Shin-Ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Takashi Nagayama, Kento Umino, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Masahiro Ashizawa, Masuzu Ueda, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Shin-Ichiro Fujiwara, Yoshinobu Kanda
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. Blood 140 (6) (2022)

Hirotomo Nakashima.css-eqlu8i{font-size:small;padding-left:4px;}